Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say

Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say
The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA — a group of major U.S. pharmaceutical

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.


  1. Lance Packer says:

    OK. This is all very nice and optimistic and sounds like everything is being done. However, what about the elephant in the room that no one wants to discuss? I’m talking about off-label prescription of already approved drugs which research has shown to have potential for repurposing for Alzheimer’s. From my experience, nobody seems to want to touch that route–neither individual physicians nor institutions. Why? The most obvious conclusion is that there is no money to be made from using out-of-patent or generic drugs. So, no sponsorship of research, etc. It is estimated that 20% of all drug prescriptions to patients generally are made on an off-label basis–except for Alzheimer’s. This is unconscionable and must be changed. As an Alzheimer’s caregiver, I am tired of watching my wife fade away while big Pharma exploits my grief for its monetary gain. Where are the voices of reason and compassion in this tragedy?

  2. Robert Sabin says:

    I am a researcher testing a new AD Drug. It escapes me why Pharma would not want to patent an existing generic for a new use?
    Most of the toxicity work has been completed, just plug the new drug in…

  3. Zachary Yim says:

    Why is intranasal insulin not mentioned? Insulin resistance, hypometabolism of glucose in the brain has been repeatedly mentioned by top-notch research groups in the field in the past as well as most recent publications in 2017 as the cause and an avenue of therapy for AD – especially in view of the failures of amyloid/tau focused approaches. There are ongoing clinical studies on AD, post-stroke cognition impairment, HAND – HIV-associated Neurocognitive Disorder….

  4. David Gregoire says:

    When are we going to see the mentioning of microglia and neuropeptides activation in these discussions? at best, the amyloid antagonists seem to be a wag the dog approach…

  5. The real breakthrough is we have reached a tipping point in Alzheimer’s research. We now know a causal factor of Alzheimer’s is Aluminum accumulation in the brain. We also know dissolved silica facilitates the elimination of Aluminum and stabilizes or improves the cognition of those with Alzheimer’s. Look at Dennis N Crouse’s book Prevent Alzheimer’s, Aluminum and Stroke with 7 Supplements, 7 Lifestyle choices and a Dissolved Mineral. Chapter 1 is available on his website.

Leave a Comment

Your email address will not be published. Required fields are marked *